Due to the substantial antitumor activity of novel HER2-targetedantibody-drug conjugates(ADCs) in HER2-low-positive BC, great interest has been increased about the clinical features of this BC subtype [26–28]. The gene discussed is ERBB2; the disease is breast cancer.